148 -4 (66) 2024 - Kazakova E.I., Ibadullaeva N.S. - FIRST RESULTS OF MOLECULAR GENETIC RESEARCH OF RESISTANT HCV STRAINS

FIRST RESULTS OF MOLECULAR GENETIC RESEARCH OF RESISTANT HCV STRAINS

Kazakova E.I. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Ibadullaeva N.S. - The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Musabaev E.I. The Research Institute of Virology of the Republican specialized scientific and practical medical center of epidemiology, microbiology, infectious and parasitic diseases, Uzbekistan

Resume

Viral hepatitis C is an important problem in modern health care, with a high mortality rate from complications such as cirrhosis and primary liver cancer. The use of direct antiviral drugs can completely cure the disease. Improved access to free HCV testing and treatment as part of the elimination program shows that resistant strains of HCV are emerging. Research into this problem is a key component to the complete elimination of this disease.

Keywords: hepatitis C virus, strain, sequencing, mutation, resistance, sensitivity.

First page

815

Last page

817

For citation: Kazakova E.I., Ibadullaeva N.S., Musabaev E.I. - FIRST RESULTS OF MOLECULAR GENETIC RESEARCH OF RESISTANT HCV STRAINS//New Day in Medicine 4(66)2024 815-817 https://newdayworldmedicine.com/en/article/3758

List of References

  1. https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c.
  2. Süsser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients // Hepatology., 50(6):1709-18, 2009.
  3. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435// Antimicrob Agents Chemother., 54(5):1878-87, 2010
  4. Murakami E, Imamura M, Hayes CN, Abe H, Hiraga N, Honda Y, Ono A, Kosaka K, Kawaoka T, Tsuge M, Aikata H, Takahashi S, Miki D, Ochi H, Matsui H, Kanai A, Inaba T, McPhee F, Chayama K. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin//Antimicrob Agents Chemother., 58(4):2105-112, 2014
  5. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators.Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection// N Engl J Med., 370(20):1889-98, 2014
  6. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G.Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials//PLoS One., 7(4):e34372, 2012
  7. Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A, Maring C, Collins C. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor// Antimicrob Agents Chemother., 59(3):1505-11, 2015
  8. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir// Hepatology., 61(1):56-65, 2015
  9. Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials// Clin Infect Dis., 59(12):1666-74, 2014
  10. Sorbo et al., Drug Resistance Update 2018// EASL guidelines 2018

    file

    download